key: cord-0264589-ya0iooec
authors: Singh, Abhimanyu K.; Martinez, Sergio E.; Gu, Weijie; Nguyen, Hoai; Schols, Dominique; Herdewijn, Piet; De Jonghe, Steven; Das, Kalyan
title: Sliding of HIV-1 reverse transcriptase over DNA creates a transient P pocket – Targeting P-pocket by fragment screening
date: 2021-07-04
journal: bioRxiv
DOI: 10.1101/2021.07.03.451029
sha: 620e713d6e3b534ea718e22bbf63b61ae14fd70b
doc_id: 264589
cord_uid: ya0iooec

HIV-1 reverse transcriptase (RT) slides over an RNA/DNA or dsDNA substrate while copying the viral RNA to a proviral DNA. We report a crystal structure of RT/dsDNA complex in which RT overstepped the primer 3’-end of a dsDNA substrate and created a transient P-pocket at the priming site. We performed a high-throughput screening of 300 drug-like fragments by X-ray crystallography and identified binding of two to P-pocket, which is composed of structural elements from polymerase active site, primer grip, and template-primer that are resilient to drugresistance mutations. Analogs of a fragment were synthesized of which two showed noticeable RT inhibition. An engineered RT/DNA aptamer complex trapped the transient P-pocket in solution. Structures of the RT/DNA complex were determined with a fragment and a synthesized analog bound at P-pocket by single-particle cryo-EM. Identification of P-pocket and the devised structurebased platform provide an opportunity for designing new types of polymerase inhibitors.

Antiretroviral therapy (ART) that is used for treating HIV infection combines three or more antiviral drugs. Individual antiviral drugs (https://hivinfo.nih.gov/understanding-hiv/factsheets/fda-approved-hiv-medicines) have been developed to block different steps of the viral lifecycle -namely the virus attachment and fusion, reverse transcription, integration of viral DNA to the host-cell DNA, and maturation of released viral particles. 1 HIV treatment is life-long and various drug combinations are used to prevent the emergence of drug-resistant viruses such that the plasma viral load in infected individuals remains undetectable. Periodically new drugs are introduced to overcome drug resistance and toxicity that emerge due to the long-term use of existing drugs. 2 Ideally, a new drug is expected to have a mechanism of action that is different from those of the existing drugs. For example, fostemsavir, a gp120 inhibitor, was FDA approved in 2020 primarily for treating multi-drug resistant HIV infection 3 . Also, new drugs with improved profile against existing targets are being explored; cabotegravir, which is an integrase strand transfer inhibitor, was approved as the most recent HIV drug. The lessons learned from targeting and suppressing drug resistance in HIV have broader implications in understanding and treating infectious diseases and cancer. 4 HIV-1 reverse transcriptase (RT) copies the viral ~10 kilobase ssRNA genome to a dsDNA in a multi-step process. 5 For the DNA synthesis, RT binds an eighteen base-pair stretch of a duplex substrate with the primer 3'-end nucleotide occupying the priming site (P site). A dNTP complementing the first template overhang binds the N site and the nucleotide part is catalytically incorporated by RT at the 3'-end of the primer with the release of pyrophosphate. Following each nucleotide incorporation, the DNA is translocated from N to P site to accommodate the next dNTP.

Approved RT-inhibiting drugs are non-nucleoside RT inhibitors (NNRTIs) and nucleoside/nucleotide RT inhibitors (NRTIs). NNRTIs allosterically block DNA polymerization by binding a pocket adjacent to the polymerase active site. In general, NRTIs are DNA-chain terminators i.e., an NRTI being a modified nucleotide is incorporated into a growing DNA strand and blocks the addition of next nucleotide. RT is responsible for the catalytic incorporation of NRTIs, and RT mutations confer NRTI resistance. The nucleotide analogs are also used for treating infections by RNA viruses that carry RNA-dependent RNA-polymerases for transcription and replication of viral RNAs; for example, sofosbuvir 6 and remdesivir 7 are nucleotide analogs used to treat hepatitis C and SARS-CoV-2 infections, respectively.

A polymerase can be directly inhibited by small molecules that would block NTP/dNTP binding to the N site. For HIV-1 RT, the nucleoside-competing RT inhibitors (NcRTIs) have been investigated as potential drug candidates. Unlike an NRTI, NcRTIs do not require cellular phosphorylation steps. NcRTIs compete with dNTPs for binding at the N site and can be categorized as metal-dependent inhibitors such as a-CNP 8-10 and metal-independent inhibitors such as INDOPY-1. 11, 12 Despite these developments, discovery of new druggable sites of RT that are highly conserved are important for developing new classes of drugs with resilience to existing drug-resistance mutations.

In general, the transient states have been considered as important targets for drug design 13 , and there may exist unidentified transient states of HIV-1 RT that can be valuable for discovering new classes of drugs. During the polymerization process, RT has been shown to slide over its substrate by single-molecule FRET studies, 14, 15 which indicates potential for the existence of transient states, however, no transient state has been structurally characterized. In this study, we crystallized HIV-1 RT/dsDNA in a new crystal form with two copies of the complex present in the crystallographic asymmetric unit; in one, the primer 3'-end nucleotide occupies the N site representing the pre-translocation complex (N complex) and in the other copy, RT slides ahead of dsDNA such that the primer 3' terminus occupies P-1 site (P-1 complex). A transient pocket is formed at the P site in this P-1 complex. We refer the pocket as P-pocket hereafter. Fragment screening is a valuable experimental technique to find new druggable pockets or new chemical scaffolds for binding to an existing pocket. 16 We screened 300 fragments from the DSi-Poised 17 and Fraglites 18 libraries by X-ray crystallography using the state-of-the-art facility Xchem 19 at Diamond Light Source (UK) and identified two compounds (048 and 166) binding at P-pocket, which is flanked by highly conserved structural motifs. We performed structure-based virtual screening of related compounds and synthesized five close analogs of the fragment 166. Using a modified DNA aptamer, we trapped the P-1 state in solution with P-pocket available for inhibitor binding. Structures of the hit fragment 166 and a newly synthesized analog F04 bound at P-pocket were determined by single-particle cryo-electron microscopy (cryo-EM).

Our study revealed a highly conserved transient P-pocket that is created in the process of sliding of RT over a dsDNA substrate and established an experimental platform for structure-based drug design using single-particle cryo-EM. This finding opens the possibility for discovering new classes of RT inhibitors, and may help extend the concept for identifying and targeting analogous pockets in other viral polymerases.

Earlier, I63C RT cross-linked with a 27/20-mer template/primer dsDNA (Fig. 1a ) was crystallized as a polymerase active complex in which, the primer 3'-end occupied the P site (P complex; Fig. 1b ) and an incoming d4T-TP was bound at the N site; two copies of this ternary I63C RT/DNA/d4T-TP complex were present in the asymmetric unit. 20 In the current study, we crystallized the above I63C RT/dsDNA crosslinked binary complex in a new crystal form (Supplementary Table 1 ) that contains two copies of the complex, and the structure was determined at 2.85 Å resolution. No dNTP was added and therefore, we expected both copies in crystal were of P-complex. Surprisingly, we observed that in the first copy, RT has backtracked over the DNA by one nucleotide length such that the primer 3'-end nucleotide occupies the N site, and the structure represents the state following a nucleotide incorporation and prior to translocation (N complex; Fig. 1c ). Functionally, RT backtracks as an N complex for excision, the reverse reaction of polymerization that RT facilitates to excise nucleoside analogs such as AZT from the primer 3'-end. 21, 22 In second copy in the crystallographic asymmetric unit, RT has slipped ahead of the DNA substrate by about one nucleotide length such that the primer 3'-end occupies P-1 site (P-1 complex; Fig. 1d ).

For structural studies of catalytic-competent RT/dsDNA complex, RT is usually crosslinked to a modified DNA base. The predominantly used crosslinking is done between a mutated residue Q258C of the thumb subdomain and a modified guanine base of template or primer which is the fifth nucleotide from the P site. 23, 24 The Q258C crosslinking prevents sliding of RT over DNA and arrests a stable complex for structural studies. The Q258C crosslinking was used to obtain the structures of both N-and P-complexes of RT/DNA when appropriate DNA substrate was crosslinked. 22 Similarly, the N-and P-complexes have been also trapped using a DNA aptamer that resists RT translocation. 9, 25 In contrast, the structures of N, P, and P-1 complexes (Figs. 1b, c, d) achieved by using I63C RT/DNA crosslinked complex reveal that the flexible fingers subdomain and the single-strand part of the DNA on either side of the crosslinked disulfide bond permit sliding of RT over the dsDNA substrate by at least three-nucleotide length. The crosslinked dAMP on the template overhang occupies N+2, N+1, and N positions in the structures of N, P, and P-1 complexes, respectively (Fig. 1e ).

The crystals of I63C RT/DNA complex unexpectedly contain an N complex and a P-1 complex in the crystallographic asymmetric unit rather than two copies of the P complex. What is the basis for the structural heterogeneity in the current crystals which is rather uncommon? In general, a protein or complex is crystallized at a low energy state. For DNA synthesis, RT/dsDNA in solution is required to exist as the P complex which permits the binding of an incoming dNTP at the N site. Following the nucleotide incorporation, the N complex is formed and then translocated to the P complex. These complexes in solution, however, are in dynamic equilibrium with a higher probability of existing as the P complex for accommodating an incoming dNTP.

Apart from attaining the N complex, RT/DNA is also expected to visit multiple transient states that are short-lived. The dynamic behavior of RT flipping and sliding over a dsDNA or an RNA/DNA substrate have been observed by single-molecule FRET studies. 14, 15, 26 Our current crystallization requires Cd 2+ ions and the structure revealed that two active site Mg 2+ ions in the N complex have been replaced by two Cd 2+ ions (Fig. 1f) ; significantly strong scatterer Cd 2+ ions that has 46 electrons compared to Mg 2+ ions that has 10 electrons produced strong electron density peaks; Cd 2+ ions were unambiguously located in the structure. The structure implies that higher chelation affinity of Cd 2+ ions compared to that of Mg 2+ ions stabilized the RT/DNA as the N complex in the first copy. Biochemically, Cd 2+ ions have been shown to inhibit DNA polymerization by RT even at a low concentration of 1-10 µg/ml. 27 In the crystal structure, two active-site Cd 2+ ions trap the N complex and block translocation. Also, the chelation geometry of both Cd 2+ ions at the active site deviate from the classic octahedral chelation geometry observed for Mg 2+ ions in a catalytic active complex 28 suggesting that the Cd 2+ ion chelation is not competent for carrying out catalytic reaction. Strong yet non-productive chelation of Cd 2+ ions at the active site appears to be responsible for RT inhibition.

In the crystal structure, we observed that the other end of DNA of this N complex structure has extended beyond the RNase H active site and interacts with the DNA of the second copy of the complex in the asymmetric unit ( Supplementary Fig. 1 ). The guanine base of the template 3'end nucleotide (Fig. 1a ) of the first copy is intercalated between the duplex DNA and adjacent 3'end guanine overhang of the second copy of the complex, and vice versa for the 3'-end guanine overhang of the second copy. This DNA:DNA interaction at the non-crystallography symmetry interface, which is not present in the P complex structure of the I63C RT/DNA, 20 appears to be primarily responsible for stabilizing the P-1 complex of RT in the second copy while the first copy is stabilized as the N complex by active site Cd 2+ ions (Figs. 1f and 1g ). An experiment to replace the Cd 2+ with Mg 2+ ions by transferring the crystals to the crystallization buffer without CdCl2 dissolved the crystals immediately suggesting that Cd 2+ ion is essential for the stability of the crystal. Also, crystals never grew in the absence of Cadmium.

The sliding of RT/DNA to the P-1 complex (Supplementary Movies 1 and 2) creates a transient P-pocket, and the crystal lattice contacts stabilize the open pocket conformation suggesting that the energy required for creating and stabilizing this pocket is not high. P-pocket is located between two key structural elements -the active site YMDD motif and the primer grip;

both are conserved and essential for the DNA polymerization by HIV-1 RT. Blocking this pocket by small molecules would inhibit RT. We used a one-of-a-kind high-throughput XChem fragment screening facility at the Diamond Light Source, UK to find chemical scaffolds that can bind Ppocket ( Fig. 2 ). We used a subset of 300 fragments from FragLites 18 and brominated DSI-Poised 17 libraries provided by the XChem facility. The subset was chosen for its high solubility in ethylene glycol as our crystals were more resilient to ethylene glycol than to organic solvents like DMSO.

The diffraction datasets were collected unattended using the automated data collection setup at the I04-1 beamline. The datasets were processed through the automated data processing pipeline available at I04-1. However, owing to their moderate resolution, only thirty best datasets were selected for manual processing, structure solution, and difference map calculations. The analysis of the diffraction datasets revealed the binding of two fragments 166 and 048 to P-pocket (Fig. 2 ).

The detailed experimental protocol is described in the experimental section and schematically shown in Supplementary Fig. 2 . The central cyclopropyl moiety is positioned over the conserved YMDD motif of the polymerase active site and interacting with the active-site residues Y183, M184, and D185. Consequently, the YMDD hairpin has bent down by ~1.6 Å compared to the apo structure. One Mg 2+ ion that was chelating all three catalytic aspartates (D110, D185, and D186) in the apo structure, is dissociated upon binding of 166. The primer grip has moved away from the inhibitor by ~1 Å, which is the least among all structural motifs forming walls of P-pocket. The phenyl ring of 166 points towards the first template overhang thymine base. This thymine base, which is less ordered in the apo structure due to lack of interaction, has shifted by ~2.2 Å and aligned with the phenyl ring of 166. 

Like fragment 166, fragment 048 (2-(4-bromo-1H-pyrazol-1-yl)-N-cyclopropyl-Nmethylacetamide; Fig. 4a ) binds at P-pocket with a clear electron density (Fig. 4b) . The fragment 048 is smaller in size containing two rings -a cyclopropyl and a pyrazole. The cyclopropyl group is the only chemical moiety common to both fragments 048 and 166, and the cyclopropyl group occupies a common part of P-pocket in both structures despite two fragments fill different parts of the pocket. The cyclopropyl ring is positioned over the YMDD hairpin in the pocket (Fig. 4c) , and like 166, fragment 048 binding knocks out the active site Mg 2+ ion. The 4-bromopyrazole ring interacts with the residues Y115 and Q151 (Fig. 4d) 

To investigate if the newly discovered P-pocket can accommodate analogs of 166 with potential for improving binding affinity, we initiated a docking study targeting P-pocket in the RT/DNA/166 structure. The aim was to evaluate various chemical substitutions to the azolecyclopropyl-phenol backbone that mimics the binding of a nucleotide (Fig. 3f) . The rationale behind the design of a virtual library of analogs of 166, is described in the supplementary section "Fragment design and docking study". A total of 84 fragments were designed virtually with the aim to (i) form base-pair-like interaction with the template first overhang dTMP, (ii) engage one or more invariant catalytic aspartates or (iii) both (Supplementary Table 2 Table 3 and Supplementary Fig. 3 ). Detailed of synthesis for F01-F05

is outlined in the supplementary section "Synthesis of fragments".

Next, in an attempt for engaging the catalytic aspartates, fragments F19-F84 were designed where the amide bond was substituted for an amidine or guanidine linker (Supplementary Table   2 ). The docking result suggested that amidine and guanidine can form hydrogen bond or salt bridge interactions with D185 and/or D186 and two fragments, F47 and F81, were selected for synthesis ( Supplementary Fig. 4 ). In addition, newly introduced heteroaromatics have the potential to form additional hydrogen bonds with surrounding residues. Synthesis of F47 or F81 has not been successful yet.

The Cd 2+ ions play a significant role in stabilizing the N and P-1 complexes in crystal.

Twenty-seven ordered Cd 2+ ions are located in the asymmetric unit, and Cd 2+ ions interact with DNA template and primer near P-pocket (Fig. 1g) . Additionally, this crystal form is not very robust for soaking compounds. Presumably, soaking of fragments at high concentrations might be interfering with the positioning of Cd 2+ ions and the crystal stability. Often, we experienced that the apo crystals are dissolved or lose diffraction quality upon fragment soaking.

Single-particle cryo-electron microscopy (cryo-EM) has emerged as an effective technique for structural studies of macromolecular systems at or near-atomic resolution, 29 and the technique can be powerful for structure-based drug design 30 when a sample is optimized for generating good quality vitreous grids reproducibly and by efficient data acquisition and fast processing.

Additionally, for our current target, we required to trap the RT/DNA P-1 complex in solution for cryo-EM studies. The following paragraph explains the rationale for trapping the complex carrying P-pocket in solution state.

A selective evolution of ligands by exponential enrichment (SELEX) based screening discovered a nucleic acid template:primer aptamer that binds RT with significantly higher affinity than a typical template:primer substrate. 31 Supplementary Fig. 6a) suggesting a minimum impact of the experimental conditions of earlier crystallization or current cryo-EM grid preparation on the protein and DNA aptamer. A primary aim for determining the structure of RT/DNA aptamer/166 P-1 complex by both cryo-EM and crystallography is to assess the impacts of two distinct techniques on (i) the characteristics of the transient pocket and (ii) binding of the fragment that has a relatively weak affinity. The cryo-EM density map revealed the binding of fragment 166 to P-pocket (Fig. 5a) where 166 stacks with the P-1 DNA base-pair as in the crystal structure (Fig. 5b) . A superimposition of structures of RT/DNA aptamer/166 P-1 complex determined by cryo-EM and crystallography in the current study ( Supplementary Fig. 6b) show that the conformation and the mode of binding of 166 in two structures are similar, however, not identical (Fig. 5c) . The observed structural changes may be attributed to the distinctly different experimental conditions. Considering that the P-1 complex represents a transient state, involvement of Cd 2+ ions with DNA nucleotides (Fig. 1g) The cryo-EM density in P-pocket of RT/DNA aptamer/F04 complex clearly defined the location and confirmation of the fragment (Fig. 5d) . The fragment F04 was synthesized as a racemic mixture, and the cryo-EM density suggests that binding of the (R,R)-enantiomer is favored. The fragment was predicted to have hydrogen-bond interaction with thymine base of the first template overhang. In structure, although the pyridine ring pointed towards the thymine base of dTMP, it failed to develop a strong H-bond with the base. F04 is stacked with the first base-pair of DNA duplex at the P-1 position (Fig. 5e) , and this stacking interaction appears to be improved when compared to the stacking of 166. Better density for F04 than for 166 in their respective cryo-EM structures may relate to the improved stacking interactions of F04 with the P-1 base-pair.

Because of almost identical experimental conditions, the RT and DNA conformations in both 166 and F04 complexes are highly superimposable even at their P-pocket; both structures align on Ca atoms with rmsd of 0.74 Å. Thereby, the difference in the positioning of the fragments in the pocket may be attributed to the differences in their chemical structures.

Our current fragments are weak binders that lack significant specific interactions with Ppocket residues. Moreover, for RT polymerase assay, the presence of dNTP would shift equilibrium of RT/DNA to P complex that would compete with the formation of transient P-pocket and binding of a fragment to the pocket. Addition of dNTP would also increase the rate of dissociation of a bound fragment. The above facts suggest that high-affinity binders of P-pocket are required for reliable measurement of inhibition. For our current fragments, we used a qualitative RT gel-based incorporation assay 33 to examine if any of the synthesized fragments shows some inhibition of DNA polymerization by RT; details are in experimental section. Our assay demonstrated weak, but noticeable, RT inhibition by the fragments F03 and F05 at 10 mM concentration advocating P-pocket as a promising druggable pocket (Fig. 5g) . Compounds F01 -F05 have a common pyrimidine ring replacing the phenyl ring of 166, whereas different 5membered heterocycles are substituted for the thiazole ring. The RT inhibition assay results show that a pyrazole ring or a 1,2,4-triazole is favorable for RT inhibition. The data in the realm of the structure of F04 complex suggests that a nitrogen at position 1 can form a hydrogen-bond with D186.

RT was shown to slide over an RNA/DNA or a dsDNA substrate in the process of DNA synthesis. Here for the first time, we trapped a transient state in which RT has slide ahead of DNA by one nucleotide distance and created a pocket, P-pocket. In the absence of dNTP, the binary I63C RT/DNA cross-linked complex was more flexible in solution, and the crystal contacts helped trap a transient state of RT/DNA complex that carried P-pocket. Using X-ray crystallography, we screened 300 small-molecule fragments and discovered the binding of two fragments to P-pocket.

The mode of binding of fragment 166 mimics the positioning of the primer 3'-end nucleotide in the catalytic P complex. The binding of 166 suggested a potential for pseudo-base-pair-like interaction with the first template overhang at one end and expansion of the fragment to gain interaction with the catalytic triad (D110, D185, and D186) from the opposite end. We designed such compounds virtually and docked those in P-pocket. Five selected compounds with simple chemical modifications and improved docking score compared to 166 were synthesized, and two of those showed inhibition of DNA polymerization by HIV-1 RT. We used an RT/DNA aptamer complex that trapped the transient P-pocket in solution without needing help from crystal lattice contacts or Cd 2+ ions that were required for crystallization. The RT/DNA aptamer in complexes with two fragments were optimized on cryo-EM grids and the structures of the complexes were determined from single-particle data collected using an in-house Glacios 200kV transmission electron microscope. The optimization of samples on cryo-EM grids and data collection protocol reproducibly yielded high-quality data from less than one thousand micrographs. These optimizations are essential for high throughput structural study for a drug-design project using single-particle cryo-EM.

The current fragments provide a basic chemical scaffold that can bind the transient Ppocket and thereby defines a novel druggable site of HIV-1 RT. There exist multiple opportunities to design compounds with pocket-specific interactions such as pseudo A:T or G:C base-pairing and extension to reach active-site, primer grip, and key residues such as Y115 and M151 that are involved in dNTP binding; binding of fragment 048 indicates the potential for acquiring interactions with Y115 and M151. While our study provides the basis for exploring a novel site of RT for drug design, the current fragment scaffold that mimics a nucleotide may also have a broader implication for finding inhibitors of RNA polymerase inhibiting in an analogous mechanism. This study also advocates for utilizing combinations of powerful biophysical and biochemical techniques in uncovering and validating transient pockets.

The RT containing I63C mutation (RT139A) was constructed and purified as described. 16 Briefly, after Ni-NTA purification, the His-6 tag was cleaved from the N-terminus of p51 using 1:10 mass ratio of GST-tagged HRV14 3C protease to RT, overnight on ice. Purification continued with Mono Q.

To generate a 28-mer template with a cross-linking dA at the second base overhang, the oligomer 

For cryo-EM studies, we used an RT construct that has D498N mutation (RT127A) at the RNase H active site as previously reported 34 ; the D498N mutation blocks RNase H activity, but exhibits polymerase activity comparable to wild-type RT. The expression and purification of D498N mutant RT was carried out as previously described. 34 Briefly, E. coli BL21-CodonPlus (DE3)-RIL cells harbouring RT expression construct was allowed to grow until OD600 reached 0.9, induced with 1 mM IPTG, followed by further shaking for 3 h at 37 ºC. The cells were harvested, lysed by sonication (Branson Sonifier SFX250) and clarified by centrifugation. The cleared lysate was loaded onto a 5 ml Ni-NTA column (GE Healthcare) connected to a FPLC system (GE healthcare) and purification was performed following the manufacturer's instructions. A final ionexchange purification using a Mono-Q column (GE healthcare) was carried out, and the protein was buffered exchanged into 10 mM Tris-HCl pH 8.0 and 75 mM NaCl. Tris-HCl pH 8.0, 75 mM NaCl. The major peak eluted at retention volume of ~13 mL contained the RT-aptamer complex as confirmed by OD260:OD280 measurement and peak shift relative to unbound RT ( Supplementary Fig. 5 ). The complex was aliquoted and stored at -80 ºC until further use.

Screening of fragments on cross-linked RT crystals were performed at one-of-a-kind high throughput facility Xchem 35 at Diamond Light Source, UK. The semi-automated platform and experimental steps involved in this x-ray crystallography-based fragment screening schematically summarized in Supplementary Fig 2. Briefly, 300 fragments were transferred into 300 crystal drops, and the crystal soaking was done for 1-3 hours at 20 °C in fragments at concentrations between 10-30 mM. The fragment were selected from DSi-Poised 17 and Fraglites library 18 that were stored at 100 mM concentration in ethylene glycol, and dispensed into the crystal drops using an acoustic dispenser. 36 Crystals were mounted manually on Litholoops (Molecular Dimensions, Sheffield, UK) and diffraction datasets were collected at beamline I04-1 in unattended mode. Data sets were processed using automated processing pipelines available at Diamond Light Source. After inspection, thirty best datasets were processed manually using iMosflm, 37 and structures were solved using Phaser in the PHENIX package 38 , then peaks in 2Fo-Fc and Fo-Fc maps were inspected for fragment density.

Chemical structures of designed ligands were drawn using ChemBioDraw Ultra 14.0, energy minimized by MM2 method, and saved in pdb format. Asymmetric unit copy of the RT/dsDNA exhibiting the P-pocket was selected out from the co-crystal structure with 166. The receptor grid was defined around the fragment binding site, as dictated by the 166 co-crystal structure, using AutoDock Tools 1.5.4 graphical interface. 39 The grid box size was set to 22x22x18 xyz points and its center designated at dimensions (x, y and z) -129.599, -2.922 and 13.379. After imparting partial atomic charges, the receptor was saved in pdbqt file format. Ligands were also imparted with partial charges and saved in pdbqt format. Docking of the ligands was performed with AutoDock High resolution data sets for both fragment complexes were collected on the Glacios using EPU software version 2.9.0 (ThermoFisher Scientific). Electron movies were collected in the counting mode at a nominal magnification of 150,000x yielding a pixel size of 0.97 Å. The total exposure time was 55 seconds with a total dose of 50 e -/Å 2 in 40 frames and the movies were recorded as gain corrected MRC files. The data collection parameters are listed in Supplementary Table 4 .

All frames in individual movies were aligned using MotionCor2 43 as implemented in Relion-3.1

and contrast transfer function (CTF) estimations were performed using CTFFIND-4 44 . The particles were picked using the Laplacian-of-Gaussian auto-picking routine in Relion-3.1. Good particles were selected using 2D-class averaging and 3D classification. Initial low-resolution 3D reference map for the 3D classification was generated from the crystal structure of RT/aptamer DNA (PDB Id. 5HP1) using Chimera 45 . The final set of particles for each structure were generated after cycles of 2D and 3D classifications, and the particles were re-extracted. The gold-standard auto-refined maps were further improved by B-polishing and Ctf-refinement. The final autorefined map for each structure was B-sharpened using the post-processing routine in Relion-3.1.

All data processing was carried out by Relion-3. 

The RT inhibition assay was carried out using a Cy5-flurophore labeled primer (5′-Cy5-CAGGAAACAGCTATGAC) and a template ( Competing interests. Authors declare no competing interest.

Correspondence and requests for materials should be addressed to K. D.

(kalyan.das@kuleuven.be) 

HIV drug development: the next 25 years

HIV Drug Resistance -An Emerging Threat to Epidemic Control

Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection

Managing drug resistance in cancer: lessons from HIV therapy

HIV-1 reverse transcription

Sofosbuvir for previously untreated chronic hepatitis C infection

Remdesivir for the Treatment of Covid-19 -Final Report

Alpha-carboxy nucleoside phosphonates as universal nucleoside triphosphate mimics

Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet

Exploring the role of the alpha-carboxyphosphonate moiety in the HIV-RT activity of alpha-carboxy nucleoside phosphonates

Indolopyridones inhibit human immunodeficiency virus reverse transcriptase with a novel mechanism of action

Structural Basis of HIV-1 Inhibition by Nucleotide-Competing Reverse Transcriptase Inhibitor INDOPY-1

Enzymatic Transition States and Drug Design

Slide into action: dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates

Single-Molecule Analysis of Reverse Transcriptase Enzymes

Fragment-based screening using X-ray crystallography and NMR spectroscopy

A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain

FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation

Achieving a Good Crystal System for Crystallographic X-Ray Fragment Screening

Structure of HIV-1 reverse transcriptase/d4TTP complex: Novel DNA cross-linking site and pH-dependent conformational changes. Protein science : a publication of the

Structures of reverse transcriptase pre-and post-excision complexes shed new light on HIV-1 AZT resistance

Structural basis of HIV-1 resistance to AZT by excision

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

Trapping HIV-1 reverse transcriptase before and after translocation on DNA

Structure of HIV-1 reverse transcriptase bound to a novel 38-mer hairpin template-primer DNA aptamer. Protein science : a publication of the

Dynamic binding orientations direct activity of HIV reverse transcriptase

Inhibition of HIV-1 infection by zinc group metal compounds

DNA polymerases: structural diversity and common mechanisms

Resolution advances in cryo-EM enable application to drug discovery

The potential of cryo-electron microscopy for structure-based drug design

Selection of primer-template sequences that bind human immunodeficiency virus reverse transcriptase with high affinity

Duplex structural differences and not 2'-hydroxyls explain the more stable binding of HIV-reverse transcriptase to RNA-DNA versus DNA-DNA

Iminodipropionic acid as the leaving group for DNA polymerization by HIV-1 reverse transcriptase

Crystal engineering of HIV-1 reverse transcriptase for structurebased drug design

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Gentle, fast and effective crystal soaking by acoustic dispensing

Integrating macromolecular X-ray diffraction data with the graphical user interface iMosflm

PHENIX: a comprehensive Python-based system for macromolecular structure solution

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Cluster : A method for clustering biological molecules coupled with visualization in the Pymol Molecular Graphics System

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

CTFFIND4: Fast and accurate defocus estimation from electron micrographs

UCSF Chimera--a visualization system for exploratory research and analysis

Coot: model-building tools for molecular graphics

Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix